Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Henry Ford Hospital, Detroit, Michigan Columbia University Medical Center - Herbert Irving Pavilion, New York, New York Duke University, Durham, North Carolina The Cleveland Clinic, Cleveland, Ohio Brown University Health/Rhode Island Hospital, Providence, Rhode Island UT MD Anderson Cancer Center, Houston, Texas University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah